AstraZeneca Spies Success For Antibody To Prevent COVID-19 Infection In Vulnerable
Could Be First With Pre-Exposure Authorization
Executive Summary
While it is likely to be fourth to market, AstraZeneca’s long-acting antibody combination could help the US battle SARS-CoV-2 in vaccine-skeptical states, data from study suggests.
You may also be interested in...
Coronavirus Update: J&J Highlights Positive Booster Shot Data
Also, Moderna completed the submission of the BLA for mRNA-1273’s FDA approval, Pfizer starts a rolling submission for a booster shot and Brii Biosciences announced data for its two-antibody antiviral cocktail, and Japan withdraws selected lots of Moderna's vaccine over contamination worries.
Regeneron’s Antibody Therapy A Lifesaver In Seronegative COVID-19 Patients
Identifying patients who have not mounted an immune response to SARS-CoV2 and treating them with the antibody cocktail cuts risk of death by a fifth.
Antibody-Drug Conjugates Take Their Place On The ASCO 2023 Stage
Investment from big and small players against existing and novel targets is making antibody-drug conjugates one of the fastest-growing fields in oncology, as attested by their presence at the upcoming ASCO meeting.